Davies FE - Search Results

1

Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma.

Brioli A, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ. Brioli A, et al. Among authors: davies fe. Leuk Lymphoma. 2013 Sep;54(9):1975-81. doi: 10.3109/10428194.2012.760736. Epub 2013 Jan 23. Leuk Lymphoma. 2013. PMID: 23270579

2

Detection and quantitation of the CBFbeta/MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML.

Evans PA, Short MA, Jack AS, Norfolk DR, Child JA, Shiach CR, Davies F, Tobal K, Liu Yin JA, Morgan GJ. Evans PA, et al. Leukemia. 1997 Mar;11(3):364-9. doi: 10.1038/sj.leu.2400578. Leukemia. 1997. PMID: 9067575

3

Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.

Rawstron AC, Owen RG, Davies FE, Johnson RJ, Jones RA, Richards SJ, Evans PA, Child JA, Smith GM, Jack AS, Morgan GJ. Rawstron AC, et al. Among authors: davies fe. Br J Haematol. 1997 Apr;97(1):46-55. doi: 10.1046/j.1365-2141.1997.72653.x. Br J Haematol. 1997. PMID: 9136941 Free article.

4

p53 gene mutations in multiple myeloma.

Owen RG, Davis SA, Randerson J, Rawstron AC, Davies F, Child JA, Jack AS, Morgan GJ. Owen RG, et al. Mol Pathol. 1997 Feb;50(1):18-20. doi: 10.1136/mp.50.1.18. Mol Pathol. 1997. PMID: 9208809 Free PMC article.

5

The use of biological variables to predict outcome in multiple myeloma.

Davies FE, Jack AS, Morgan GJ. Davies FE, et al. Br J Haematol. 1997 Dec;99(4):719-25. Br J Haematol. 1997. PMID: 9432013 Free article. Review. No abstract available.

6

B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors.

Rawstron AC, Davies FE, Owen RG, English A, Pratt G, Child JA, Jack AS, Morgan GJ. Rawstron AC, et al. Among authors: davies fe. Br J Haematol. 1998 Jan;100(1):176-83. doi: 10.1046/j.1365-2141.1998.00525.x. Br J Haematol. 1998. PMID: 9450807 Free article.

7

True spectrum of 14q32 translocations in multiple myeloma.

Pratt G, Fenton JA, Proffitt JA, Rawstron AC, Davies FE, Child JA, Morgan GJ. Pratt G, et al. Among authors: davies fe. Br J Haematol. 1998 Dec;103(4):1209-10. doi: 10.1046/j.1365-2141.1998.1161d.x. Br J Haematol. 1998. PMID: 9886346 Free article. No abstract available.

8

Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma.

Pratt G, Wiles ME, Rawstron AC, Davies FE, Fenton JA, Proffitt JA, Child JA, Smith GM, Morgan GJ. Pratt G, et al. Among authors: davies fe. Hematol Oncol. 1998 Jun;16(2):47-55. doi: 10.1002/(sici)1099-1069(199806)16:2<47::aid-hon622>3.0.co;2-3. Hematol Oncol. 1998. PMID: 10065112

9

FICTION-TSA analysis of the B-cell compartment in myeloma shows no significant expansion of myeloma precursor cells.

Davies FE, Rawstron AC, Pratt G, O'Connor S, Su'ut L, Blythe D, Fenton J, Claydon D, Child JA, Jack AS, Morgan GJ. Davies FE, et al. Br J Haematol. 1999 Jul;106(1):40-6. doi: 10.1046/j.1365-2141.1999.01506.x. Br J Haematol. 1999. PMID: 10444161 Free article.

10

High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

Davies FE, Rollinson SJ, Rawstron AC, Roman E, Richards S, Drayson M, Child JA, Morgan GJ. Davies FE, et al. J Clin Oncol. 2000 Aug;18(15):2843-51. doi: 10.1200/JCO.2000.18.15.2843. J Clin Oncol. 2000. PMID: 10920132

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

365 results

Search Page

Filters